[{"abstract": "In a second bid for its British rival, the American drug giant Pfizer on Friday increased its offer by 7 percent. But AstraZeneca said the terms substantially undervalued the company.", "web_url": "https://dealbook.nytimes.com/2014/05/02/pfizer-raises-bid-for-astrazeneca-putting-pressure-on-drug-maker-to-make-deal/", "snippet": "In a second bid for its British rival, the American drug giant Pfizer on Friday increased its offer by 7 percent. But AstraZeneca said the terms substantially undervalued the company.", "lead_paragraph": "The British drug maker AstraZeneca rejected an improved offer by its American rival Pfizer on Friday as political debate in Britain intensified over whether a foreign takeover of one of the country\u2019s largest pharmaceutical firms should be encouraged.", "print_section": "B", "print_page": "3", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/03/business/SubPfizer1/SubPfizer1-articleLarge.jpg", "height": 400, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2014/05/03/business/SubPfizer1/SubPfizer1-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 400}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/03/business/SubPfizer1/SubPfizer1-jumbo.jpg", "height": 683, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/03/business/SubPfizer1/SubPfizer1-superJumbo.jpg", "height": 1366, "width": 2048, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/03/business/SubPfizer1/SubPfizer1-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2014/05/03/business/SubPfizer1/SubPfizer1-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/03/business/SubPfizer1/SubPfizer1-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "AstraZeneca Rejects a Higher Bid From Pfizer", "kicker": "DealBook", "content_kicker": null, "print_headline": "AstraZeneca Turns Down Higher Bid From Pfizer", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 1, "major": "N"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 2, "major": "N"}, {"name": "subject", "value": "Stocks and Bonds", "rank": 3, "major": "N"}, {"name": "organizations", "value": "AstraZeneca PLC", "rank": 4, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 5, "major": "N"}, {"name": "organizations", "value": "Warner-Lambert Co", "rank": 6, "major": "N"}, {"name": "glocations", "value": "Great Britain", "rank": 7, "major": "N"}], "pub_date": "2014-05-02T06:37:11+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Chad Bray and Stephen Castle", "person": [{"firstname": "Chad", "middlename": null, "lastname": "Bray", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}, {"firstname": "Stephen", "middlename": null, "lastname": "Castle", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 2}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/081db4c0-b546-5458-9399-1c4fff4be721", "word_count": 1010, "uri": "nyt://article/081db4c0-b546-5458-9399-1c4fff4be721"}, {"abstract": "Federal authorities are looking into traders who traffic in Herbalife\u2019s stock. | AstraZeneca rejected a sweetened offer by Pfizer. | Ares is set to debut on the public market. | K.K.R. seeks to attract smaller investors.", "web_url": "https://dealbook.nytimes.com/2014/05/02/morning-agenda-scrutiny-for-traders-of-herbalife/", "snippet": "Federal authorities are looking into traders who traffic in Herbalife\u2019s stock. | AstraZeneca rejected a sweetened offer by Pfizer. | Ares is set to debut on the public market. | K.K.R. seeks to attract smaller investors.", "lead_paragraph": "U.S. LOOKS INTO WAGERS ON HERBALIFE \u00a0|\u00a0 \u201cThree federal agencies and one billionaire hedge fund manager have placed Herbalife under the microscope, scrutinizing whether the diet supplements company is a pyramid scheme,\u201d Ben Protess and Alexandra Stevenson write in DealBook. \u201cBut Herbalife is not the only one under investigation. Some federal authorities are pursuing other inquiries that might expand the regulatory gaze from Herbalife to the traders who traffic in the company\u2019s stock.\u201d", "source": "The New York Times", "multimedia": [], "headline": {"main": "Morning Agenda: Scrutiny for Traders of Herbalife", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [], "pub_date": "2014-05-02T11:54:06+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Sydney Ember", "person": [{"firstname": "Sydney", "middlename": null, "lastname": "Ember", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/ac4795d9-71a2-5ba3-a967-ff0287c457c2", "word_count": 1934, "uri": "nyt://article/ac4795d9-71a2-5ba3-a967-ff0287c457c2"}, {"abstract": "Pfizer\u2019s latest offer for its rival seems cheap to shareholders who view AstraZeneca\u2019s turnaround as well advanced, Neil Unmack writes in Reuters Breakingviews.", "web_url": "https://dealbook.nytimes.com/2014/05/02/pfizer-has-yet-to-make-a-compelling-bid-to-astrazenecas-shareholders/", "snippet": "Pfizer\u2019s latest offer for its rival seems cheap to shareholders who view AstraZeneca\u2019s turnaround as well advanced, Neil Unmack writes in Reuters Breakingviews.", "lead_paragraph": "Pfizer\u2019s courtship of AstraZeneca looks like a hate-hate relationship. In January, the British pharmaceutical firm AstraZeneca viewed its larger rival\u2019s takeover proposal of 46.61 pounds a share as too low on cash, too risky, and too cheap to even talk about. Pfizer\u2019s latest proposal, an effort to get AstraZeneca to begin friendly talks, hasn\u2019t moved the needle much.", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/03/business/dbpix-ian-read/dbpix-ian-read-articleLarge.jpg", "height": 444, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2014/05/03/business/dbpix-ian-read/dbpix-ian-read-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 444}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/03/business/dbpix-ian-read/dbpix-ian-read-jumbo.jpg", "height": 758, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/03/business/dbpix-ian-read/dbpix-ian-read-superJumbo.jpg", "height": 1516, "width": 2048, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/03/business/dbpix-ian-read/dbpix-ian-read-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2014/05/03/business/dbpix-ian-read/dbpix-ian-read-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/03/business/dbpix-ian-read/dbpix-ian-read-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "Pfizer Has Yet to Make a Compelling Bid to AstraZeneca\u2019s Shareholders", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 1, "major": "N"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 2, "major": "N"}, {"name": "organizations", "value": "AstraZeneca PLC", "rank": 3, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 4, "major": "N"}, {"name": "glocations", "value": "Great Britain", "rank": 5, "major": "N"}], "pub_date": "2014-05-02T17:00:17+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Neil Unmack", "person": [{"firstname": "Neil", "middlename": null, "lastname": "Unmack", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/ec8aaf84-5b1a-5c5f-9984-1ea85ce62151", "word_count": 403, "uri": "nyt://article/ec8aaf84-5b1a-5c5f-9984-1ea85ce62151"}]